Eurofins Scientific SE stock (FR0014000MR3): shares little changed after recent CAC 40 performance

Eurofins Scientific SE shares traded broadly stable on Euronext Paris at the start of the week after a solid 12?month performance within the CAC 40, with investors watching the French testing specialist ahead of the next corporate newsflow.

Eurofins Scientific SE shares started the new week on Euronext Paris trading broadly sideways, with the stock recently quoted around the mid-50-euro range after closing a prior session at 58.74 EUR, according to finanzen.net data referencing CAC 40 constituents as of late May 2026. The France-based laboratory testing specialist remains part of the CAC 40 index, keeping investor attention on how it will navigate sector trends in pharmaceuticals, food safety and environmental testing over the coming quarters.

For domestic investors in France, the primary listing of Eurofins Scientific SE is on Euronext Paris under the ticker ERF, with trading in EUR and inclusion in the flagship CAC 40 benchmark, which provides it with high visibility among institutional and retail investors alike. European investors also frequently access the shares via German trading venues such as Tradegate or Xetra, where the stock is typically quoted in euros and offers an additional route to gain exposure to the company’s diversified testing activities.

The stock traded at 58.74 EUR on Euronext Paris at the close of the referenced prior trading day, according to finanzen.net as of 05/31/2026, illustrating how the share price has broadly consolidated after a period of stronger 12?month performance within the CAC 40. In Germany, the stock has also seen regular trading via Tradegate in euros, offering investors in the DACH region a liquid alternative venue for the company’s shares alongside the French home market.

Against this market backdrop, investors are focusing on Eurofins Scientific SE’s ability to leverage its global laboratory network and specialized testing services to capture demand in areas such as pharmaceutical development, food and environmental testing, and advanced genomics. The company’s broad geographic presence across Europe, North America and other regions, alongside its track record of acquisitions and network expansion, is a key factor in how the stock is assessed within the CAC 40, even on days when no new company-specific announcements are published.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Eurofins
• Sector/industry: Laboratory testing, inspection and certification services
• Headquarters/country: Luxembourg, France
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Pharmaceutical and biotech testing, food and feed testing, environmental and industrial testing, specialty genomics and clinical diagnostics services
• Home exchange/listing venue: Euronext Paris (ERF)
• Trading currency: EUR

Eurofins Scientific SE: core business model

Eurofins operates a global network of laboratories that provide specialized analytical testing services for pharmaceuticals, food, environment and clinical diagnostics, with revenue primarily generated from recurring contracts and project-based work across regulated industries.

What banks and research houses say about Eurofins Scientific SE

No verified analyst coverage was identified at the time of publication.

Conclusion

Eurofins Scientific SE shares are trading broadly stable on Euronext Paris after a year of notable performance within the CAC 40, with the previous close at 58.74 EUR providing a recent reference point for investors. The lack of fresh analyst commentary in today’s newsflow means attention is focused instead on how the company’s global testing activities in pharmaceuticals, food and environment will feed into future earnings updates and potentially shape the next move in the stock price.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.